Last update 01 Nov 2024

Foreign-Body Reaction

Last update 01 Nov 2024

Basic Info

Synonyms

Foreign Body Reaction, Foreign body reaction, Foreign-Body Reaction

+ [9]

Introduction

Chronic inflammation and granuloma formation around irritating foreign bodies.

Drugs associated with Foreign-Body Reaction

Ascorbic Acid/Menadione

Target

NF-κB

Mechanism

NF-κB inhibitors [+1]

Active Org.

Summa Health System (Ohio) [+1]

Originator Org.

Ic Medtech Corp.

Active Indication

Joint Diseases [+1]

Inactive Indication

Edema [+5]

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Foreign-Body Reaction

ACTRN12623000114640 / CompletedNot ApplicableIIT

Intraoperative PVP-I (Povidone Iodine) antiseptic wash and complication rates in breast prosthesis surgery, analysis of observational Australian Breast Device Registry (ABDR) data

Start Date24 Sep 2021

Sponsor / Collaborator-

NCT05017337 / RecruitingNot ApplicableIIT

A Translational Study of Breast-implant assocIated anaplastIc Large Cell Lymphoma and Capsular Contracture

BASILICA is a UK NIHR Biomedical Research Centre funded study recruiting patients at The Royal Marsden NHS Foundation Trust. The study aims to obtain blood and tissue samples from patients with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), capsular contracture and implant-naïve patients undergoing primary implant insertion surgery for translational scientific analysis.

Start Date27 Jul 2021

Sponsor / Collaborator

Royal Marsden NHS Foundation Trust

NCT04834310 / WithdrawnPhase 4IIT

Postoperative Antibiotics Following Primary and Secondary Breast Augmentation: A Double-Blinded, Randomized Trial

Postoperative antibiotics are routinely used for implant-based breast augmentation at the investigators' institution. From 2017-2019, the investigators' institution has conducted approximately 270 primary and secondary breast augmentation procedures. Current plastic surgery literature does not provide recommendations for antibiotic prophylaxis following implant-based breast procedures. Despite controversy surrounding their utility during the postoperative course, postoperative antibiotics have become commonplace for many plastic surgeons. To date, strong scientific evidence supporting this practice is minimal and based largely on anecdotal evidence and limited studies, including poorly controlled retrospective and non-blinded prospective series. The goal of this study is to conduct a prospective randomized trial to assess whether extended antibiotic prophylaxis is necessary to prevent infection and long-term complications (e.g. capsular contracture) in patients undergoing augmentation mammoplasty with implants. The investigators' anticipate that extended antibiotic prophylaxis is not required. The rationale for discontinuing postoperative antibiotics is based on the following: (1) a single dose of preoperative intravenous antibiotics has been demonstrated to be sufficient prophylaxis for most breast surgeries and (2) there are patient safety concerns associated with prolonged antimicrobial use such as the development of resistant bacterial strains and clostridium-related infections. Concrete evidence that extended antibiotic prophylaxis is not required would encourage plastic surgeons to practice better antibiotic stewardship and help stymie the rise of drug-resistant organisms.

Start Date01 Apr 2021

Sponsor / Collaborator

University of California, Los Angeles

100 Clinical Results associated with Foreign-Body Reaction

100 Translational Medicine associated with Foreign-Body Reaction

0 Patents (Medical) associated with Foreign-Body Reaction

2,297

Literatures (Medical) associated with Foreign-Body Reaction

01 Oct 2024·Advanced Science

WRN Nuclease‐Mediated EcDNA Clearance Enhances Antitumor Therapy in Conjunction with Trehalose Dimycolate/Mesoporous Silica Nanoparticles

Article

Author: Li, Yinan ; Li, Yingying ; Zhong, Weilong ; Liu, Huijuan ; Sun, Tao ; Chen, Yang ; Huang, Xiu ; Chen, Caihong ; Qiao, Qingqing

AbstractCurrent research on tumor fibrosis has focused on cancer‐associated fibroblasts, which may exert dual functions of tumor promotion and inhibition. Little attention has been paid to whether tumor cells themselves can undergo fibrotic transformation and whether they can inhibit parenchymal cells similar to pulmonary fibrosis, thus achieving the goal of inhibiting the malignant progression of tumors. To explore the significance of inducing tumor fibrosis for cancer treatment. This study utilizes mesoporous silica nanoparticles (MSN) loaded with Trehalose dimycolate (TDM) to induce tumor cell fibrosis through the dual effects of TDM‐induced inflammatory granuloma and MSN‐induced foreign body granuloma. The results show that TDM/MSN (TM) can effectively induce tumor fibrosis, manifested specifically by collagen internalization, and suppression of proliferation and invasion capabilities, suggesting the potential role of tumor fibrosis therapy. However, further investigation reveals that extrachromosomal DNA (ecDNA) mediates resistance to fibrosis induction. To comprehensively enhance the efficacy, WRN exonuclease is conjugated to TM to form new nanoparticles (TMW) capable of effectively eliminating ecDNA, globally promoting tumor cell fibroblast‐like transformation, and validated in a PDX model to inhibit cancer progression. Therefore, TMW, through inducing tumor cell fibrosis to inhibit its malignant progression, holds great potential as a clinical treatment strategy.

01 Oct 2024·World Neurosurgery

Giant Epidermoid Cyst of the Scalp Growing for 76 Years

Article

Author: Wen, Wenjuan ; Shi, Chuanying ; Du, Junwei

Epidermoid cysts are prevalent noncancerous cutaneous lesions known to exhibit unusually extended periods of growth. In this study, we present a remarkable case of an epidermoid cyst located on the scalp, which exhibited a growth period of 76 years, the longest growth time documented in the literature to date. The presence of the mass was noted at birth, and it exhibited gradual growth throughout the years, with a notable acceleration observed during the final 2 years. The patient underwent a surgical excision, and the histopathological analysis was consistent with epidermoid cyst, featuring localized rupture and demonstrating foreign body granulomatous inflammation. This case highlights the ability of epidermoid cysts to manifest as slow-growing entities over an exceptionally prolonged timeframe. Furthermore, instances of rapid growth may be attributed to a combination of mass rupture and inflammatory processes.

01 Oct 2024·Journal of Cutaneous Pathology

Antiperspirant‐related zirconium and aluminum‐containing granulomas; histopathology and in situ chemical analysis

Article

Author: Sanford, Jeffrey A. ; Curcio, Christian A. ; Candelaria‐Santiago, Roberto ; Strausborger, Stacy L. ; Lewin‐Smith, Michael R. ; Allbritton, Jill I. ; Forte, Dominic M.

AbstractThe potential adverse health effects of antiperspirant use are of interest to patients, primary care providers, dermatologists, and pathologists. In rare instances, antiperspirants containing aluminum–zirconium complexes have been associated with granulomatous dermatoses despite being deemed non‐sensitizing in experiments. In this case study, we present a detailed examination of an axillary granuloma in a 28‐year‐old female who had been using an aluminum–zirconium‐based antiperspirant for several years and presented with a left axillary nodule that was excised and analyzed using scanning electron microscopy with energy‐dispersive x‐ray analysis (SEM/EDXA). Histopathological examination revealed a foreign body‐type reaction with amphophilic granular material within giant cells that corresponded to collocated zirconium and aluminum on SEM/EDXA elemental maps. Our case adds to the limited reports of axillary granulomas related to aluminum–zirconium complexes. It illustrates the histopathological appearance and in situ distribution of the aluminum–zirconium complexes, supporting the formation of foreign body‐type granulomas. Additionally, our case study illustrates the potential role of these compounds in such reactions and aims to increase awareness among pathologists and clinicians.

News (Medical) associated with Foreign-Body Reaction

29 Apr 2024

·www.prnewswire.com

PhaseOne Health Highlights Long-term Outcomes of Using Hypochlorous Acid at The Aesthetic Meeting 2024

HOCl effective in reducing recurrent capsular contracture in secondary cases over a 5 year follow up period. VANCOUVER, BC, April 29, 2024 /PRNewswire/ -- PhaseOne Health President and CEO Jeff Nugent announced the company's participation in The Aesthetic Meeting 2024 which is being held May 2-5 in Vancouver, BC, Canada. PhaseOne Health is a leader in infection protection, providing medical professionals with superior solutions for the improvement of clinical outcomes and the management of risk. The authors will present the benefits of a unique application of hypochlorous acid (HOCl) used during secondary breast surgery. The paper emphasizes both the efficacy of HOCl as a surgical prep solution and the low rates of recurrent capsular contracture post-operatively.* This result is notable based on the minimal recurrence of capsular contracture over a 5 year follow up period in secondary cases, particularly in this complex group of patients. The presentation will take place at the Aesthetic Meeting on Friday, May 3rd at 10:00AM in the Aesthetic Arena located in the exhibit hall. There is a reception scheduled for 5:30pm Saturday, May 4th at Tap and Barrel, adjacent to the Aesthetic Meeting space. A presentation and discussion of these results will be held with Jack Fisher MD, Dennis Hammond MD, Bruce Van Natta MD, and Roger Wixtrom PhD. All interested are invited to attend. * Xia, MD, T., Hasan, S., Halpern, MD, J., Van Natta, MD, B., & Lund, MD, H. (2024). Long-Term Outcomes of 0.5% Hypochlorous Acid Pocket Irrigation in Revision Aesthetic Breast Surgery. PhaseOne Health was established in 2019 with the mission of providing superior solutions for reducing the microbial risks associated with surgical procedures and the treatment of wounds. That's why we manufacture our HOCl via a proprietary chemical manufacturing process. It's also why we use UV resistant amber glass to ensure the purity and stability of our product for maximum available HOCl when used. The team at PhaseOne Health cares about getting it right. That's why we go the extra mile to make sure that PhaseOne is the best. This press release was issued through 24-7PressRelease.com. For further information, visit . SOURCE PhaseOne Health

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Foreign-Body Reaction

Basic Info

Related

Analysis